{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-268135","form_type":"8-K","ticker":"CUE","cik":"0001645460","company_name":"Cue Biopharma, Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.029417+00:00","generated_at":"2026-05-16T23:44:33.368396+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cue Biopharma licenses CUE-100 series to ImmunoScape; receives $15M cash and 40% equity","bullets":["Collaboration with ImmunoScape to develop 'Seed-and-Boost' TCR-T cell therapy for solid tumors using CUE-100 series.","Cue Biopharma receives $15M upfront ($10M in Q4 2025, $5M in Nov 2026) and 40% equity stake in ImmunoScape.","Cue Biopharma eligible for high-single-digit royalties on net sales of any products developed.","IND-enabling studies on track for 2027 submission; preclinical data shown in pancreatic and ovarian cancer models.","Cue Biopharma to focus on autoimmune disease programs while oncology development advances with ImmunoScape."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-268135","json":"https://secwatch.observer/filing/0001193125-25-268135.json","markdown":"https://secwatch.observer/filing/0001193125-25-268135.md","text":"https://secwatch.observer/filing/0001193125-25-268135.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645460/000119312525268135/0001193125-25-268135-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645460/000119312525268135/cue-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:44:33.368396+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}